Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 9.80
-0.26 (-2.58%)
Sep 10, 2026, 1:14 PM HKT
Ascletis Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.95 | 2.03 | 1.28 | 56.6 | 54.09 | 76.88 | |
Revenue Growth | -59.94% | 58.07% | -97.73% | 4.63% | -29.64% | 119.64% |
Cost of Revenue | 0.54 | 1.5 | 0.55 | 30.61 | 78.78 | 37.7 |
Gross Profit | 0.41 | 0.53 | 0.74 | 25.99 | -24.69 | 39.17 |
Selling, General & Admin | 62.73 | 75.23 | 101.74 | 116.02 | 52.18 | 50.82 |
Research & Development | 603.9 | 409.05 | 302.39 | 216.78 | 267.1 | 213.32 |
Other Operating Expenses | 32.67 | 0.77 | 1.23 | 2.14 | 4.64 | 5.5 |
Operating Expenses | 699.31 | 485.06 | 405.37 | 334.94 | 323.93 | 269.64 |
Operating Income | -698.9 | -484.53 | -404.63 | -308.95 | -348.62 | -230.47 |
Interest Expense | -0.15 | -0.16 | -0.24 | -0.14 | -0.16 | -0.13 |
Interest & Investment Income | 75.11 | 65.68 | 92.24 | 99.28 | 47.48 | 24.99 |
Earnings From Equity Investments | - | - | -5.27 | -20.28 | -22.89 | -17.88 |
Currency Exchange Gain (Loss) | -14.47 | -5.67 | 4.15 | 9.7 | 60.18 | -16.44 |
Other Non Operating Income (Expenses) | 37.9 | 37.9 | 21.16 | 6.7 | 4.35 | 40.9 |
EBT Excluding Unusual Items | -600.52 | -386.79 | -292.61 | -213.69 | -259.65 | -199.02 |
Gain (Loss) on Sale of Investments | 9.52 | 27.41 | 2.25 | 68.97 | - | - |
Asset Writedown | - | - | -10.58 | - | -55.19 | - |
Pretax Income | -591 | -359.37 | -300.94 | -144.72 | -314.84 | -199.02 |
Income Tax Expense | 0.6 | 0.51 | - | - | - | - |
Earnings From Continuing Operations | -591.6 | -359.88 | -300.94 | -144.72 | -314.84 | -199.02 |
Net Income | -591.6 | -359.88 | -300.94 | -144.72 | -314.84 | -199.02 |
Net Income to Common | -591.6 | -359.88 | -300.94 | -144.72 | -314.84 | -199.02 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,011 | 973 | 1,002 | 1,074 | 1,087 | 1,098 |
Shares Outstanding (Diluted) | 1,011 | 973 | 1,002 | 1,074 | 1,087 | 1,098 |
Shares Change | 3.74% | -2.90% | -6.75% | -1.19% | -0.96% | 5.53% |
EPS (Basic) | -0.59 | -0.37 | -0.30 | -0.13 | -0.29 | -0.18 |
EPS (Diluted) | -0.59 | -0.37 | -0.30 | -0.13 | -0.29 | -0.18 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -574.01 | -418.42 | -343.67 | -230.01 | -209.53 | -151.9 |
Free Cash Flow Per Share | -0.57 | -0.43 | -0.34 | -0.21 | -0.19 | -0.14 |
Gross Margin | 42.87% | 25.99% | 57.29% | 45.92% | -45.65% | 50.96% |
Operating Margin | -73801.48% | -23892.11% | -31538.04% | -545.88% | -644.51% | -299.79% |
Profit Margin | -62470.96% | -17745.56% | -23455.65% | -255.70% | -582.07% | -258.88% |
Free Cash Flow Margin | -60613.62% | -20632.10% | -26786.75% | -406.40% | -387.38% | -197.59% |
EBITDA | -687.02 | -472.39 | -390.45 | -294.89 | -322.49 | -204.83 |
EBITDA Margin | - | - | - | - | - | -266.45% |
D&A For EBITDA | 11.88 | 12.15 | 14.18 | 14.05 | 26.13 | 25.64 |
EBIT | -698.9 | -484.53 | -404.63 | -308.95 | -348.62 | -230.47 |
EBIT Margin | - | - | - | - | - | -299.79% |